Patient reported outcomes for non-tuberculous mycobacterial disease Source: Eur Respir J, 55 (1) 1902204; 10.1183/13993003.02204-2019 Year: 2020
A study of patients with pulmonary tuberculosis and confirmed coexistence of nontuberculous mycobacteria during treatment: Does the use of the additional acid-fast bacilli sputum test lead to shorter hospitalization? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014
Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease Source: Eur Respir J, 55 (1) 1901300; 10.1183/13993003.01300-2019 Year: 2020
Long-term follow-up study of patients with pneumoconiosis complicated by nontuberculous mycobacterial lung disease: report of four cases Source: Eur Respir J 2001; 18: Suppl. 33, 443s Year: 2001
What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey Source: ERJ Open Res, 7 (1) 00807-2020; 10.1183/23120541.00807-2020 Year: 2021
Treatment outcomes of non tuberculous mycobacterial (NTM) pulmonary disease. Multicenter study Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020
When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
Pulmonary diseases due to non-tuberculous mycobacteria in TB referral clinical center Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011
The light at the end of the tunnel: is COPD prevalence changing? Source: Eur Respir J 2010; 36: 718-719 Year: 2010
Non-tuberculous mycobacterial disease in patients who were referred as MDR-TB in resource limited settings: need for more rapid identification Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs Source: Eur Respir J , 49 (4) 1700374; DOI: 10.1183/13993003.00374-2017 Year: 2017
Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Clinical outcome of multiple nontuberculous mycobacteria infection among people with bronchiectasis in Taiwan: a cohort study Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020
Double impact: Difficulties in treating patients with liver diseases from tuberculosis Source: Annual Congress 2011 - Tuberculosis in special populations Year: 2011
Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK Source: Eur Respir J, 56 (4) 2000045; 10.1183/13993003.00045-2020 Year: 2020
Pulmonary infection with nontuberculous mycobacteria: management and follow up of 5 infected patients Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement Source: Eur Respir J, 51 (3) 1800170; 10.1183/13993003.00170-2018 Year: 2018
Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease Source: Eur Respir J, 53 (5) 1801636; 10.1183/13993003.01636-2018 Year: 2019
Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Nontuberculous mycobacterial disease: an important cause of morbi-mortality in HIV infected subjects Source: Eur Respir J 2003; 22: Suppl. 45, 333s Year: 2003